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A b s t r a c t
There is no doubt nowadays that statins exert a diabetogenic action. The evidence comes from observational studies, ran-
domised trials, and meta-analyses. The relationship between statin use and new-onset type 2 diabetes is associated with statin 
potency and dose. It seems also to be stronger if the lowering effect is stronger and the low-density lipoprotein cholesterol 
level achieved is lower. The mechanisms underlying the development of diabetes in statin-treated patients are not completely 
understood. Generally, the increased insulin resistance and decreased insulin secretion are taken into account. However, it 
should be kept in mind that the cardiovascular risk reduction effect of statins outweighs the harm related to diabetes induc-
tion. The patients at risk of diabetes development should be monitored with regard to the parameters of glucose metabolism. 
The introduction of preventive lifestyle modifications to prevent diabetes is recommended. New-onset diabetes should be 
managed according to the guidelines.
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INTRODUCTION
Observational studies [1–6], controlled clinical trials [7, 8], 
and meta-analyses [9–14] indicate that statins induce diabe-
tes, and intensive statin therapy is more diabetogenic than 
moderate-intensity therapy [15, 16]. This issue has been of 
interest only since 2008, when a primary prevention trial 
with rosuvastatin was published, showing a 44% reduction 
in the rate of cardiovascular events versus placebo (relative 
risk [RR] 0.56; 95% confidence interval [CI] 0.46–0.69) 
but also a 25% higher risk of diabetes (RR 1.25; 95% CI 
1.05–1.49) [7]. At the time of that publication, statins had 
already been in use for 20 years. These findings prompted 
a search for associations between statin treatment and the 
risk of diabetes in other studies, as well as for possible un-
derlying pathomechanisms.
OBSERVATIONAL STUDIES
Observational studies showed an increase in the risk of type 
2 diabetes in statin users compared to non-users, which was 
higher than in randomised clinical trials.
In the Women’s Health Initiative study, an association 
between incident diabetes and statin use was evaluated in 
153,840 postmenopausal women aged 50 to 79 years with-
out diabetes at baseline [2]. Statins were taken by 10,884 of 
these women (7.04% of the study population). Statin use at 
baseline was associated with a 48% higher risk of incident type 
2 diabetes (hazard ratio [HR] 1.48, 95% CI 1.38–1.59) during 
more than one million person-years of follow-up (adjusted for 
many potential confounders). All statins were diabetogenic. 
Diabetes was self-reported.
The METSIM study cohort included 8749 subjects aged 
45 to 73 years without diabetes at baseline [3]. The median 
duration of follow-up was 5.9 years. The risk of diabetes 
among statin users was 46% higher compared to non-users 
(HR 1.46, 95% CI 1.22–1.74). Insulin sensitivity was lower 
by 24%, and b-cell function (disposition index) was lower 
by 12%. Most statin users were treated with simvastatin 
(65.9%), followed by atorvastatin (18.1%), rosuvastatin (8.6%), 
fluvastatin (3.8%), lovastatin (2.3%), and pravastatin (1.3%). 
Diabetes was diagnosed based on fasting blood glucose 
levels, oral glucose tolerance test, HbA1c levels, or initiation 
of hypoglycaemic therapy during follow-up. Of note, this 
study was designed to evaluate the effect of statins on the risk 
of type 2 diabetes and not the risk of cardiovascular disease.
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In a retrospective study on a Korean population, based 
on the Korean National Health Insurance registry, cases of 
new-onset diabetes mellitus were evaluated in patients with 
ischaemic heart disease in whom statin therapy was initiated [4]. 
Statins were taken by 94,370 patients who were compared 
to 61,990 statin non-users. The follow-up period was from 
January 2010 to December 2012. During this time, incident 
type 2 diabetes was nearly twice as common among statin 
users (HR 1.84, 95% CI 1.63–2.09, adjusted for treatment 
intensity, individual drugs, and comorbidities). Regarding 
individual statins, atorvastatin, rosuvastatin, simvastatin, and 
lovastatin use was associated with twofold higher risk of 
diabetes. The lowest risk was seen for pravastatin (HR 1.54, 
95% CI 1.32–1.81). Data on incident diabetes were based 
on cases identified during the follow-up and prescription of 
one or more hypoglycaemic drugs.
Results of the observational Australian Longitudinal Study 
on Women’s Health, regarding cases of incident diabetes in 
elderly women treated with statins, have been recently pub-
lished [5]. The analysis included 8372 Australian women aged 
76 to 82 years without diabetes at baseline. Of these, 49% 
were treated with statins, most commonly with atorvastatin 
followed by simvastatin. The mean duration of statin therapy 
was 6.5 years. The risk of new-onset diabetes among statin 
users was 33% higher compared to non-users (HR 1.33, 95% 
CI 1.04–1.70). A dose-response effect was noted, with HR of 
1.17 (95% CI 0.84–1.65) in women treated with low statin 
doses compared to HR of 1.51 (95% CI 1.14–1.99) in those 
treated with high doses.
Lately, Italian authors published a meta-analysis of obser-
vational studies that evaluated the association between statin 
use and the risk of new-onset diabetes [6]. Publications from 
inception to 30 June 2016 were assessed, and the inclusion 
criteria for the meta-analysis were met by 18 observational 
studies and two case-control studies. The median duration 
of follow-up was 7.2 years. The risk of incident diabetes was 
44% higher in statin users compared to non-users (RR 1.44, 
95% CI 1.31–1.58). A high heterogeneity among studies was 
noted. Regarding individual statins, the highest risk of incident 
diabetes was associated with the use of rosuvastatin and ator-
vastatin (RR 1.61, 95% CI 1.30–1.98; and RR 1.49, 95% CI 
1.31–1.70, respectively). Simvastatin use was associated with 
a 38% higher risk of diabetes (RR 1.38, 95% CI 1.19–1.61). 
Pravastatin and fluvastatin were associated with the same 
diabetogenic effect (RR 1.39, 95% CI 1.09–1.77). Thus, the 
meta-analysis has confirmed that the diabetogenic effect of 
statin is a class effect.
CLINICAL TRIALS AND THEIR META-ANALYSES
As mentioned above, the first study to indicate a diabetogenic 
effect of statins was the JUPITER study [7]. It was a randomised 
clinical trial that evaluated primary prevention of cardiovas-
cular disease using rosuvastatin 20 mg daily versus placebo. 
The median duration of follow-up was 1.9 years. The trial 
was interrupted prematurely due to a highly significant 44% 
reduction in the rate of cardiovascular events (RR 0.56, 95% 
CI 0.46–0.69, p < 0.00001). However, a post hoc analysis 
revealed an excess of patients with newly diagnosed type 2 di-
abetes in the rosuvastatin group, at the rate of 3% (270 cases 
per 8901 patients in the rosuvastatin group) versus 2.4% in 
the placebo group (216 cases per 8901 patients).
The authors also analysed the rates of incident diabetes 
in relation to the presence of risk factors for diabetes. Four 
risk factors were taken into account: metabolic syndrome, 
increased fasting glucose (100–125 mg/dL), body mass index 
(BMI) ≥ 30 kg/m2, and HbA1c level > 6%. In patients without 
risk factors for type 2 diabetes (n = 6095), the risk was not 
increased compared to placebo (HR 0.99, 95% CI 0.45–2.21). 
In contrast, the risk of incident diabetes was 28% higher in 
those with one or more risk factors for diabetes (n = 11,508; 
HR 1.28, 95% CI 1.07–1.54).
Of note, however, a significant reduction in the rate 
of cardiovascular events was noted in both groups (with or 
without risk factors for diabetes): by 39% (HR 0.61, 95% CI 
0.47–0.79, p = 0001) and 52% (HR 0.48, 95% CI 0.33–0.68, 
p = 0.001), respectively.
In patients with risk factors for diabetes, 134 cardiovascu-
lar events and deaths were avoided at the cost of 54 cases of 
new diabetes, while 86 cardiovascular events were avoided 
without any cases of new diabetes in patients with no risk 
factors for diabetes. Incident diabetes was physician-reported.
Recently, the results of a randomised clinical trial, the 
Diabetes Prevention Program (DPP) study, have been re-
ported regarding risk of developing diabetes in patients who 
were or were not treated with a statin during the trial (a post 
hoc analysis) [8]. The DPP trial tested the effect of intensive 
lifestyle intervention, metformin, or placebo on the incidence 
of diabetes in patients at high risk of diabetes (n = 3234). 
At baseline, statin was used in only 4% of the participants 
compared to 33% patients in the lifestyle intervention group, 
37% patients in the metformin group, and 35% patients in 
the placebo group at 10 years of follow-up. Simvastatin and 
atorvastatin were the most commonly used statins (in 40% and 
37% of statin-treated patients, respectively). Statin use was as-
sociated with a 36% higher risk of diabetes (HR 1.36; 95% CI 
1.17–1.58), and an increase in the risk of diabetes during statin 
treatment was noted in all three intervention groups. Diabetes 
was diagnosed based on annual oral glucose tolerance tests 
and semi-annual fasting blood glucose measurements.
A comprehensive review paper regarding the association 
of statin therapy with incident diabetes has been published 
lately [9]. To summarise, it could be said that in the majority 
of the large randomised primary and secondary prevention 
trials involving different statins with data available (respectively 
eight and five), no significant increase in the relative risk of 
new-onset diabetes was observed. There was a significant 
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association of statin treatment with incident diabetes in two 
trials (JUPITER, PROSPER). Only one primary prevention 
study revealed a significant decrease in the risk of diabetes 
(WOSCOPS).
Since 2009, a number of meta-analyses have provided 
data on the diabetogenic effect of statins, indicating an ongoing 
interest in this issue. While the trials included were primarily 
designed to evaluate the effects of statins on the risk of cardio-
vascular events, post hoc analyses compared occurrence of inci-
dent diabetes in statin users and non-users as well as in patients 
receiving intensive versus moderate-intensity statin treatment. 
Below, we summarise the results of these meta-analyses in 
chronological order based on the publication date.
In 2009, Rajpathak et al. [10] reported a meta-analysis 
of six clinical trials that included 57,593 patients. The mean 
duration of follow-up was 3.9 years. Statin use was associ-
ated with a 13% higher risk of diabetes compared to control 
(RR 1.13, 95% CI 1.03–1.23), without heterogeneity among 
trials. The next meta-analysis (2010) included 13 trials with 
91,140 patients [11]. The mean duration of follow-up was four 
years. The risk of diabetes among statin users was modestly 
increased (by 9%; odds ratio [OR] 1.09, 95% CI 1.02–1.17). 
Statin treatment in 255 patients for four years was associated 
with one case of incident diabetes. In 2011, a meta-analysis 
of 76 randomised statin clinical trials was performed to 
evaluate the effect of these drugs on the risk of cardiovascular 
disease [12]. Information on incident diabetes was provided 
in 17 trials. The increase in the risk of diabetes was the same 
as in the meta-analysis by Sattar et al. [13] (OR 1.09, 95% CI 
1.02–1.17). A year later a meta-analysis of 72 randomised 
statin trials, done partly by the same authors, was conducted to 
evaluate adverse effects associated with statin use. Information 
on incident diabetes was provided in 16 of these trials [13]. 
During a mean follow-up of 2.7 years, similarly to the previ-
ous meta-analysis, the risk of diabetes in statin users was 9% 
higher compared to controls (OR 1.09, 95% CI 1.02–1.16). 
This meta-analysis was based on the same trials as the previ-
ous one. Regarding the effect of individual statins, except for 
rosuvastatin no data were available or the differences in risk 
were not significant. Rosuvastatin use (a meta-analysis of four 
trials) was associated with a significant 14% increase in the 
risk of diabetes (OR 1.14, 95% CI 1.01–1.29) [13].
Another meta-analysis published in 2013 evaluated the 
effect of various statins and their doses on the risk of develop-
ing incident diabetes [14]. The meta-analysis included 17 clini-
cal trials with 113,394 patients. The duration of follow-up 
in these studies was more than one year, and statin therapy 
was compared to placebo, or intensive statin therapy was 
compared to moderate-intensity treatment. Among statins 
tested in the included trials, the lowest risk of diabetes versus 
placebo was noted for pravastatin 40 mg per day (OR 1.07, 
95% CI 0.86–1.30). Rosuvastatin 20 mg per day was associa-
ted with a 25% higher risk (OR 1.25, 95% CI 0.82–1.90), 
and atorvastatin 80 mg per day was associated with a 15% 
increase in the risk of diabetes (OR 1.15, 95% CI 0.90–1.50). 
Despite a trend for a higher risk of diabetes among patients 
treated with intensive statin therapy, these differences were 
not statistically significant.
A recently published meta-analysis (2016) included 29 tri-
als with 163,039 patients, including 141,863 participants with 
no diabetes at baseline (18 trials) [15]. The median duration of 
follow-up was 4.8 years. A direct meta-analysis showed that 
statins as a class increased the risk of diabetes by 12% (OR 
1.12, 95% CI 1.05–1.21). A network meta-analysis revealed 
that a significant risk of diabetes was associated with the use 
of atorvastatin 80 mg per day (OR 1.34, 95% CI 1.14–1.57), 
followed by rosuvastatin (OR 1.17, 95% CI 1.02–1.35). In con-
trast, the results for simvastatin 80 mg per day and combined 
doses of individual statins were not significant. Compared with 
moderate-intensity treatment, intensive statin therapy was 
associated with a 12% higher risk of diabetes (seven studies; 
OR 1.12, 95% CI 1.01–1.24). Lipophilic statins were associ-
ated with a higher risk of diabetes compared to placebo (OR 
1.14, 95% CI 1.02–1.28). However, no increase in the risk 
was noted in a head-to-head comparison with hydrophilic 
statins (OR 1.05, 95% CI 0.9–1.23) [15].
INTENSIVE VERSUS MODERATE-INTENSITY  
STATIN THERAPY
Although some of the above studies also evaluated the effect 
of intensive statin therapy versus moderate-intensity treatment 
on the risk of new-onset diabetes, studies focused specifically 
on this issue are also available. These include meta-analyses 
by Preiss et al. [16] and Waters et al. [17]. The former was 
a meta-analysis of five statin trials that included 32,752 pa-
tients [16]. The duration of follow-up was longer than one year. 
Intensive statin therapy included atorvastatin 80 mg per day 
and simvastatin 80 mg per day, and the moderate-intensity 
treatment group included patients treated with pravastatin 
40 mg per day, atorvastatin 10 mg per day, or simvastatin 
20 to 40 mg per day. Compared to moderate-intensity treat-
ment, intensive statin therapy was associated with a higher 
risk of diabetes (OR 1.12, 95% CI 1.04–1.22) and a lower risk 
of cardiovascular events (OR 0.84, 95% CI 0.75–0.94). The 
other meta-analysis included two secondary prevention trials, 
i.e. TNT and IDEAL [17], which, too, were included in the 
analysis by Preiss et al. [16]. However, this analysis also took 
into consideration incident diabetes in relation to the presence 
of risk factors for diabetes (fasting blood glucose > 100 mg/dL, 
triglyceride level > 150 mg/dL, BMI > 30 kg/m2, and a his-
tory of hypertension). It was found that intensive atorvastatin 
therapy, compared to moderate-intensity treatment, did not 
lead to an increased risk of diabetes in patients with 0 to 1 risk 
factors for diabetes (HR 0.97, 95% CI 0.77–1.22). In contrast, 
the risk of diabetes was increased in patients with 2 to 4 risk 




Reduction in the rate of cardiovascular events with 
atorvastatin 80 mg per day, compared to moderate-intensity 
treatment, was higher in both patient subgroups, i.e. with 
0 to 1 or 2 to 4 risk factors for diabetes (HR 0.87, 95% CI 
0.755–0.995; and HR 0.82, 95% CI 0.71–0.96, respectively). 
For one additional case of diabetes, 204 patients with 2 to 4 
risk factors for diabetes had to receive intensive atorvastatin 
therapy for one year, while 242 patients had to be treated 
this way to avoid one cardiovascular event.
ASSOCIATION BETWEEN THE RISK OF INCIDENT 
DIABETES DURING STATIN THERAPY AND  
A REDUCTION IN LDL-CHOLESTEROL LEVEL
This issue may be indirectly related to compliance with 
statin therapy, as evaluated in 84,828 residents of the Italian 
Lombardy region, who were newly prescribed with a statin in 
2003 to 2004 and had their treatment compliance evaluated 
based on the number of days the drug was used (by pill count-
ing at follow-up visits) [18]. The mean duration of follow-up 
per patient was 5.5 years. Incident diabetes was identified 
based on initiation of anti-diabetic medication.
Compared to very low compliance with statin therapy, 
the rate of incident diabetes in patients with low, moderate, 
and good compliance increased by 24% (95% CI 12%–37%), 
72% (95% CI 56%–90%), and 95% (95% CI 60%–139%), 
respectively. Assuming that incident diabetes was completely 
unrelated to statin therapy in patients with very low treatment 
compliance, the proportion of diabetes attributable to statin 
use was 19% (95% CI 11%–27%), 42% (95% CI 36%–47%), 
and 49% (95% CI 38%–58%), respectively, in patients with 
low, moderate, and good compliance with statin therapy.
As can be noted above, the risk of incident diabetes in-
creased progressively with increasing compliance with statin 
therapy. At the same time, however, the risk of macrovascular 
complications of diabetes decreased progressively with in-
creasing compliance with this type of treatment.
Recent meta-analyses have also evaluated the association 
between the reduction in low-density lipoprotein cholesterol 
(LDL-C) level during statin therapy and the risk of new-onset 
diabetes [19], and between achieved lipid levels and the risk 
of diabetes [20].
The first of these meta-analyses included 14 statin tri-
als (n = 91,140), including eight studies with target LDL-C 
level < 100 mg/dL (2.59 mmol/L) or LDL-C level reduction 
by at least 30%, and showed that the rate of incident diabe-
tes during four years of treatment was related to LDL-C level 
reduction [19]. No increase in the rate of incident diabetes 
was noted in patients with LDL-C level reduction by less than 
20% or 20% to 30% compared to baseline, while the risk of 
diabetes was increased in patients with LDL-C level reduc-
tion by > 30% to 40% and > 40% to 50% (OR 1.13, 95% CI 
1.01–1.25; and OR 1.29, 95% CI 1.13–1.47, respectively). 
In terms of absolute risk, one additional case of diabetes was 
identified per 137 patients with LDL-C level reduction by 
30% to 40% and per 108 patients with LDL-C level reduction 
by 40% to 50%.
The association between statin therapy and the risk of 
incident diabetes was stronger in older patients, women, and 
patients with lower baseline LDL-C levels, lower achieved 
LDL-C levels, and a large LDL-C level reduction.
The authors concluded that LDL-C level reduction was 
the most relevant indicator of the risk of statin-induced diabe-
tes. Higher reduction of baseline LDL-C level was associated 
with a higher risk of diabetes, particularly with LDL-C level 
reduction by more than 30%.
Earlier, the same authors performed another meta-analy-
sis of the same 14 trials and showed that the rate of new-onset 
diabetes during four years of statin therapy was related to 
the achieved LDL-C levels [20]. The risk of diabetes was 
33% higher (OR 1.33, 95% CI 1.14–1.56) in patients with 
the achieved LDL-C level ≤ 70 mg/dL (1.8 mmol/L), and 
16% higher (OR 1.16, 95% CI 1.06–1.28) in those with the 
achieved LDL-C level of 70–100 mg/dL (1.8–2.59 mmol/L). 
The risk of diabetes was not increased in statin-treated patients 
with the achieved LDL-C level above 100 mg/dL.
MECHANISMS OF THE DIABETOGENIC  
EFFECT OF STATINS
Mechanisms by which statins might lead to the development of 
diabetes are unclear. Potential mechanisms include impaired 
insulin secretion and increased insulin resistance [9, 21]. This 
concept is supported by the results of the abovementioned 
METSIM study, which showed that a 46% higher risk of dia-
betes (HR 1.46, 95% CI 1.22–1.74) in statin users compared 
to non-users was accompanied by a 12% reduction in insulin 
secretion and a 24.3% increase in insulin resistance [3]. Both 
these differences compared to statin non-users were significant 
at p = 0.001. Of note, these adverse effects were related to the 
statin dose in patients treated with simvastatin or atorvastatin.
However, it is difficult to offer a truly comprehensive 
view regarding that matter because our understanding of the 
mechanisms underlying statin-induced reduction of insulin 
sensitivity and insulin secretion is still far from complete.
Reduced insulin secretion
Betteridge and Carmena discussed mechanisms of the diabe-
togenic effect of statins regarding their action on pancreatic 
b-cells, and cited in vitro studies showing that cholesterol ex-
cess in pancreatic b-cells impaired their function, proliferation, 
and survival, while cholesterol efflux improved both biological 
functions and the survival of b-cells. These effects depend on 
the LDL receptor-mediated cellular cholesterol entry [21].
This explanation of a reduced insulin secretion is also 
indirectly indicated by in vivo observations. A study using 
Mendelian randomisation showed that the effect of statins 
on the risk of incident diabetes depended on the reduction 
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of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reduc-
tase activity [22]. This is associated with an increase in LDL 
receptor activity. The tested single nucleotide polymorphisms 
in the HMG-CoA gene, i.e. rs17238484-G and rs12916, 
were selected based on genetic associations with reduced 
HMG-CoA reductase activity and lower LDL-C levels. Both 
polymorphisms were evaluated in a large population for their 
association, among others, with the risk of diabetes. The 
results showed that reduced HMG-CoA reductase activity 
was associated with a slightly increased risk of diabetes, with 
the odds ratio values of 1.02 (95% CI 1.00–1.05) for the 
rs17238848-G allele and 1.06 (95% CI 1.03–1.09) for the 
rs12916 allele. These associations may suggest that the risk 
of incident diabetes in statin users depends on the degree of 
HMG-CoA reductase activity inhibition, and thus the potency 
of a given statin.
The subsequent increase in LDL receptor activity may be 
the reason for cholesterol accumulation in b-cells and their 
dysfunction. This may be also indirectly indicated by a study 
in newly diagnosed patients with familial hypercholester-
olaemia (FH) [23]. In this study, patients were categorised 
depending on the degree of LDL receptor activity reduction 
due to mutations leading to defective or absent receptors. The 
third group were patients with apolipoprotein B (apo B) gene 
mutation. The aim of the study was to evaluate whether the 
reduced incidence of diabetes type 2 in FH is due to reduced 
cholesterol uptake by pancreatic b-cells. The presence of 
type 2 diabetes was patient-reported. The prevalence of 
type 2 diabetes was 1.75% in patients with FH and 2.93% in 
healthy relatives (OR 0.62, 95% CI 0.55–0.69, p < 0.001). The 
lowest rate was noted in patients with absent LDL receptors 
(null LDL-R), followed by those with defective receptors and 
patients with apo B gene mutation, with the respective odds 
ratios of 0.38 (95% CI 0.29–0.49), 0.49 (95% CI 0.40–0.60), 
and 0.65 (95% CI 0.48–0.87). Thus, the authors observed 
a reverse dose-response relationship between the severity of 
FH and the prevalence of type 2 diabetes.
A recent study by Spanish authors [24] is discordant 
with the above results by Besseling et al. [23]. The aim of 
the Spanish study was to evaluate the incidence of type 2 
diabetes in patients with heterozygous FH (based on the 
National Dyslipidaemia Registry of the Spanish Atheroscle-
rosis Society) and the effect of LDL-C level and the presence 
of FH-causative mutations on the risk of type 2 diabetes in 
these patients. Although the rate of incident type 2 diabetes 
was lower in patients with heterozygous FH compared to the 
general population, neither LDL-C level nor genetic mutations 
were risk factors for diabetes. The risk of diabetes was related 
to male sex, age, BMI, hypertension, baseline triglyceride 
levels, and duration of statin therapy in years.
Regardless of these findings, our current understanding of 
this issue seems to favour the hypothesis that statin-induced 
reduction of insulin secretion is associated with inhibition 
of HMG-CoA reductase activity and subsequent increase in 
LDL receptor activity in pancreatic b-cells, leading to cellular 
cholesterol accumulation.
Insulin resistance
Statins affect glucose metabolism by inhibiting its uptake in 
human adipose tissue cells, skeletal muscle cells, and pan-
creatic islet b-cells by inhibiting glucose transporter (GLUT) 
expression. This effect (reduction of GLUT4) was observed in 
adipocytes for simvastatin and atorvastatin [25, 26]. Atorvasta-
tin, pravastatin, and rosuvastatin inhibited GLUT4 in skeletal 
muscle cells, and the first two statins decreased GLUT2 ex-
pression in islet b-cells [27].
It is also worth mentioning that statins decrease glucose 
uptake in several tumour lines, but they “do not inhibit ex-
pression of GLUT proteins, and their influence on glucose 
transport can be reversed by cholesterol biosynthesis pathway 
(mevalonic acid or farnesyl pyrophosphate)” [28]. This means 
that impaired glucose uptake resulted from the inhibition 
of cholesterol synthesis, and that it can be independent of 
glucose transporters.
Statin-induced HMG-CoA reductase inhibition leads to 
a reduced synthesis of not only cholesterol but also coenzyme 
Q10, which plays an important role in GLUT4 generation. 
Thus, inhibition of coenzyme Q10 may contribute to a reduced 
expression of this glucose transporter in adipocytes, leading to 
reduced glucose uptake, as indicated by the data showing that 
the addition of coenzyme Q10 improves simvastatin-induced 
reduction of GLUT4 expression [26]. In fact, inhibition of coen-
zyme Q10 plays a role not only in insulin resistance but also in 
inhibition of insulin secretion by a reduction in the production 
of adenosine triphosphate [29].
A decrease in adiponectin level might also link statin 
therapy to insulin resistance and incident diabetes [29]. Adi-
ponectin levels show a negative correlation with abdominal 
obesity and insulin resistance [30], and high adiponectin 
levels are associated with a much lower risk of diabetes [31]. 
Proposed molecular mechanisms of the effect of adiponectin 
on insulin sensitivity include inhibition of hepatic gluconeo-
genesis, stimulation of fatty acid oxidation in the liver, and 
stimulation of glucose uptake and fatty acid oxidation in the 
skeletal muscle [30, 32]. In addition, reduced adiponectin 
level may have a negative effect not only on insulin sensitivity 
but also on insulin secretion [29]. However, the role of adi-
ponectin in the pathomechanism of the diabetogenic effect 
of statins has not been clearly established.
As mentioned above, it is difficult to provide a consistent 
and comprehensive explanation of the complicated mecha-
nisms of statin-induced development of diabetes because 
available data are still scarce. For a thorough review of some 
of these data, interested readers may be referred to recent 
papers by Lee et al. [4], Betteridge and Carmena [21], Chan 




STATINS AND CONTROL OF DIABETES
Ergou et al. [34] performed a meta-analysis of randomised sta-
tin clinical trials in patients with diabetes to evaluate the effect 
of statins on diabetes control. The meta-analysis included nine 
clinical trials (9696 participants) that provided data on HbA1c 
levels before and after the intervention. The mean duration of 
follow-up was 3.6 years. The mean HbA1c level was higher in 
statin users compared to controls (either placebo or standard 
therapy). The mean difference was 0.12% (0.04%–0.20%) or 
1.3 mmol/L (0.4–2.2 mmol/L) (p = 0.003).
A meta-analysis by Cai et al. [35], which included 
36 studies with 6875 diabetic patients, showed an adverse 
effect of intensive LDL-C level reduction on HbA1c level. The 
mean difference in HbA1c level versus placebo was 0.37% 
(95% CI 0.19–0.55) in patients with the achieved LDL-C 
level ≤ 1.8 mmol/L and 0.08% (95% CI 0.02–0.14) in those 
with the achieved LDL-C level < 2.6 mmol/L. In addition, 
intensive statin therapy resulted in a significant increase in 
HbA1c level.
SUMMARY
Observational studies and randomised clinical trials indicate 
that statins induce diabetes. This effect is stronger with more 
intensive statin therapy (statin potency and dose), higher 
LDL-C level reduction, and lower target LDL-C level. The 
diabetogenic effect of statins is also related to the presence 
of risk factors for diabetes, such as components of metabolic 
syndrome. It should be stressed, however, that the benefits of 
statins in terms of cardiovascular risk reduction outweigh any 
harm related to their diabetogenic effect. Thus, statins should 
be continued in all patients in whom these drugs are indicated 
due to high or very high cardiovascular risk, despite the risk 
of diabetes development or worsening of diabetes control, 
and these patients should be treated until they achieve the 
target LDL-C levels.
Before initiation of statin therapy the risk of diabetes 
should be assessed [1, 36, 37]. Statin-treated patients at high 
risk of developing diabetes should be monitored for changes 
in blood glucose and HbA1c levels, and preventive lifestyle 
modification should be introduced. If diabetes develops, it 
should be managed according to the guidelines.
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